Abl And Odimma Therapeutics Join Forces In Personalized Cancer Immunotherapy
PR96019
PARIS, May 17, 2022 /PRNewswire-AsiaNet/ --
ABL Europe (ABL) [https://www.abl-biomanufacturing.com/ ], a pure play contract
development and manufacturing organization (CDMO) specialized in development
and manufacturing of virus for vaccine candidates, gene and cancer therapies
and Odimma Therapeutics (Odimma)
[http://odimma-therapeutics.com/?msclkid=8fec39dac63311ec9872f2daaf949638 ] a
young biotechnological company focusing on personalized cancer immunotherapy,
announced that they have signed a development agreement. ABL will manufacture
the viral component of Odimma's innovative and proprietary immunization
platform ODI-2001. The viral component present in ODI-2001 plays the role of
both a strong immune adjuvant and of a carrier for the DNA vector expressing
personalized neoantigens. The GMP grade material produced by ABL will support
clinical trials and early commercialization.
Cancer is a leading cause of death and morbidity worldwide. According to the
World Health Organization, cancer burden rose to 19,3 million new cases and
accounted for nearly 10 million deaths in 2020(1). One of the key challenges in
the treatment of cancer is the improvement of current immunotherapies.
Tailoring the medical treatment to each patient's tumor characteristics is one
of the most promising approaches in the field.
Jean-Marc Limacher, MD, Chairman of Odimma Therapeutics said:
"The production of our viral component is the first pharmaceutical step in the
development of ODI-2001, our personalized cancer immunotherapy ready to enter
into clinic. We trust very much in the strong and historic expertise of ABL in
the bioproduction of therapeutic viruses."
Patrick Mahieux, Managing Director of ABL Europe said:
"We are proud to collaborate with Odimma and leverage our long-lasting
experience in viral vector manufacturing to contribute to bring solutions for
the most difficult cancers to treat."
(1) Source : WHO, International Agency for Research on Cancer (IARC), Media
Center – 15 Dec 2020 - Latest global cancer data: Cancer burden rises to 19.3
million new cases and 10.0 million cancer deaths in 2020 – IARC (who.int)
ABOUT ABL, AN INSTITUT MERIEUX COMPANY
ABL is a pure play contract development and manufacturing organization (CDMO)
specialized in development and manufacturing of virus for vaccine candidates,
gene and cancer therapies. ABL's mission is to provide GMP viral vectors from
development to market, contributing to the success of its clients'
immunotherapy innovations. ABL's CDMO services include bulk drug substance,
fill/finish of drug product, process and assay development, and bioanalytical
testing.
ABL is a subsidiary of the Institut Mérieux and operates from different
locations, in Europe and in the US. For more information, please visit
http://www.abl-biomanufacturing.com
ABOUT ODIMMA, AN INNOVATIVE FRENCH COMPANY
Odimma is a French biotech company with a unique approach in active
personalized cancer immunotherapy. By harnessing the ability of the patient's
own immune system to specifically recognize non-self-targets displayed by the
tumor, also called neoantigens, Odimma has designed a potent next-generation
personalized immunization platform. This proprietary platform has demonstrated
its ability to induce a powerful cellular immune response against
non-self-antigens as well as a strong anti-tumoral effect in tumor bearing
mice. By design the immunization product can be produced in a short period of
time and with no limits in the number of neoantigens to be targeted. For more
information, visit http://www.odimma-therapeutics.com
MEDIA CONTACTS:
ABL, An Institut Mérieux Company
Justine CHABROL
Head of Communications & CSR
jchabrol@ablbiomanufacturing.com
Odimma Therapeutics,
Jessica MATTA
CEO
j.matta@odimma-therapeutics.com
Logo - https://mma.prnewswire.com/media/1818530/ABL_Odimma_Therapeutics_Logo.jpg
SOURCE: ABL & Odimma Therapeutics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。